2-ME-D
Alternative Names: 2 ME-D; 2 Methoxyestradiol derivative D; 2-Methoxyestradiol DLatest Information Update: 07 Dec 2010
At a glance
- Originator AMC Cancer Research Center
- Developer Oncology Sciences Corporation
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 07 Dec 2010 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 15 Aug 2003 2-Me-D is available for licensing (http://www.oncologysciences.com)
- 05 Dec 2002 This compound is still in active development